Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Stratification Analysis and Case-control Study of Relationships between Interleukin-6 Gene Polymorphisms and Cervical Cancer Risk in a Chinese Population

  • Shi, Wen-Jing (Department of Clinical Laboratory, International Peace Maternity and Child Health Hospital of China Welfare Institute, Shanghai Jiaotong University School of Medicine) ;
  • Liu, Hao (Department of Health Technology and Informatics, The Hong Kong Polytechnic University) ;
  • Wu, Dan (Department of Obstetrics and Gynecology, International Peace Maternity and Child Health Hospital of China Welfare Institute, Shanghai Jiaotong University School of Medicine) ;
  • Tang, Zhen-Hua (Department of Clinical Laboratory, International Peace Maternity and Child Health Hospital of China Welfare Institute, Shanghai Jiaotong University School of Medicine) ;
  • Shen, Yu-Chen (Department of Clinical Laboratory, International Peace Maternity and Child Health Hospital of China Welfare Institute, Shanghai Jiaotong University School of Medicine) ;
  • Guo, Lin (Department of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai Medical College of Fudan University)
  • Published : 2014.09.15
Download PDF
⟨ Previous Next ⟩

Abstract

Interleukin-6 (IL-6), a central proinflammatory cytokine, maintains immune homeostasis and also plays important roles in cervical cancer. Therefore, we aimed to evaluate any associations of IL-6 gene polymorphisms at positions -174 and -572 with predisposition to cervical cancer in a Chinese population. The present hospital-based case-control study comprised 518 patients with cervical cancer and 518 healthy controls. Polymorphisms of the IL-6 gene were genotyped by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Patients with cervical cancer had a significantly higher frequency of the IL-6 -174 CC genotype [odds ratio (OR) =1.52, 95% confidence interval (CI) = 1.06-2.19; p=0.02], IL-6 -572 CC genotype (OR =1.91, 95% CI = 1.16-3.13; p=0.01) and IL-6 -174 C allele (OR =1.21, 95% CI = 1.02-1.44; p=0.03) compared to healthy controls. When stratifying by the FIGO stage, patients with III-IV cervical cancer had a significantly higher frequency of IL-6 -174 CC genotype (OR =1.64, 95% CI =1.04-2.61; p=0.04). The CC genotypes of the IL-6 gene polymorphisms at positions -174 and -572 may confer a high risk of cervical cancer. Additional studies with detailed human papillomavirus (HPV) infection data are warranted to validate our findings.

Keywords

References

  1. Barbisan G, Perez LO, Contreras A, Golijow CD (2012). TNF-$\alpha$ and IL-10 promoter polymorphisms, HPV infection, and cervical cancer risk. Tumour Biol, 33, 1549-56. https://doi.org/10.1007/s13277-012-0408-1
  2. Bennermo M, Held C, Green F, et al (2004). Prognostic value of plasma interleukin-6 concentrations and the -174 G>C and -572 G>C promoter polymorphisms of the interleukin-6 gene in patients with acute myocardial infarction treated with thrombolysis. Atherosclerosis, 174, 157-63. https://doi.org/10.1016/j.atherosclerosis.2004.01.019
  3. Bowcock AM, Kidd JR, Lathrop GM, et al (1988). The human “interferon-beta 2/hepatocyte stimulating factor/interleukin-6” gene: DNA polymorphism studies and localization to chromosome 7p21. Genomics, 3, 8-16. https://doi.org/10.1016/0888-7543(88)90152-8
  4. Castro FA, Haimila K, Sareneva I, et al (2009). Association of HLA-DRB1, interleukin-6 and cyclin D1 polymorphisms with cervical cancer in the Swedish population-a candidate gene approach. Int J Cancer, 125, 1851-8. https://doi.org/10.1002/ijc.24529
  5. Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC (2013). Human papillomavirus and cervical cancer. Lancet, 382, 889-99. https://doi.org/10.1016/S0140-6736(13)60022-7
  6. Fishman D, Faulds G, Jeffery R, et al (1998). The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest, 102, 1369-76. https://doi.org/10.1172/JCI2629
  7. Gangwar R, Mittal B, Mittal RD (2009). Association of interleukin-6 -174G>C promoter polymorphism with risk of cervical cancer. Int J Biol Markers, 24, 11-6.
  8. Grimm C, Six L, Tomovski C, et al (2005). A common interleukin-6 promoter polymorphism in patients with vulvar cancer. J Soc Gynecol Investig, 12, 617-20. https://doi.org/10.1016/j.jsgi.2005.08.002
  9. Grimm C, Watrowski R, Baumuhlner K, et al (2011). Genetic variations of interleukin-1 and -6 genes and risk of cervical intraepithelial neoplasia. Gynecol Oncol, 121, 537-41. https://doi.org/10.1016/j.ygyno.2011.02.019
  10. Hamaguchi M, Kawahito Y, Ishino H, et al (2011). Mucin from rheumatoid arthritis synovial fluid enhances interleukin-6 production by human peripheral blood mononuclear cells. Hum Immunol, 72, 241-8. https://doi.org/10.1016/j.humimm.2010.12.013
  11. Huang D, Zheng C, Giscombe R, et al (1999). Polymorphisms at -174 and in the 3' flanking region of interleukin-6 (IL-6) gene in patients with myasthenia gravis. J Neuroimmunol, 101, 197-200. https://doi.org/10.1016/S0165-5728(99)00140-X
  12. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  13. Kyo S, Kanaya T, Takakura M, Inoue M (2000). A case of cervical cancer with aggressive tumor growth: possible autocrine growth stimulation by G-CSF and IL-6. Gynecol Oncol, 78, 383-7. https://doi.org/10.1006/gyno.2000.5904
  14. Landi S, Moreno V, Gioia-Patricola L, et al (2003). Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Cancer Res, 63, 3560-6.
  15. Liu D, Zhou P, Zhang L, et al (2011). Differential expression of oct4 in hpv-positive and hpv-negative cervical cancer cells is not regulated by DNA methyltransferase 3a. Tumour Biol, 32, 941-50. https://doi.org/10.1007/s13277-011-0196-z
  16. Ma Y, Tang RK, Yang X, et al (2011). Lack of an association between interleukin-6 gene promoter polymorphisms (-174G/C, -572G/C) and ischemic heart disease and/or ischemic stroke: a meta-analysis. Hum Immunol, 72, 641-51. https://doi.org/10.1016/j.humimm.2011.03.019
  17. Magalhaes JF, Cortinhas AJ, Albuquerque CM, et al (2013). Interleukin-6 gene -174G>C and -636G>C promoter polymorphisms and prostate cancer risk. Mol Biol Rep, 40, 449-55. https://doi.org/10.1007/s11033-012-2079-9
  18. Mosaad YM, Fathy H, Fawzy Z, El-Saied MA (2012). Tumor necrosis factor-α -308 G>A and interleukin-6 -174 G>C promoter polymorphisms and pemphigus. Hum Immunol, 73, 560-5. https://doi.org/10.1016/j.humimm.2012.02.001
  19. Ni J, Ye Y, Teng F, Wu Q (2013). Interleukin 10 polymorphisms and cervical cancer risk: a meta-analysis. Int J Gynecol Cancer, 23, 126-33. https://doi.org/10.1097/IGC.0b013e318274b1a2
  20. Nogueira de Souza NC, Brenna SM, Campos F, et al (2006). Interleukin-6 polymorphisms and the risk of cervical cancer. Int J Gynecol Cancer, 16, 1278-82. https://doi.org/10.1111/j.1525-1438.2006.00521.x
  21. Shi TY, Zhu ML, He J, et al (2013). Polymorphisms of the interleukin 6 gene contribute to cervical cancer susceptibility in eastern Chinese women. Hum Genet, 132, 301-12. https://doi.org/10.1007/s00439-012-1245-4
  22. Shuai HL, Luo X, Yan RL, Li J, Chen DL (2012). XRCC1 polymorphisms are associated with cervical cancer risk and response to chemotherapy: a systematic review and metaanalysis. Asian Pac J Cancer Prev, 13, 6423-7. https://doi.org/10.7314/APJCP.2012.13.12.6423
  23. Slattery ML, Curtin K, Sweeney C, Wolff RK, Baumgartner RN, Baumgartner KB, Giuliano AR, Byers T (2008). Modifying effects of IL-6 polymorphisms on body size-associated breast cancer risk. Obesity, 16, 339-47. https://doi.org/10.1038/oby.2007.44
  24. Srivani R, Nagarajan B (2003). A prognostic insight on in vivo expression of interleukin-6 in uterine cervical cancer. Int J Gynecol Cancer, 13, 331-9. https://doi.org/10.1046/j.1525-1438.2003.13197.x
  25. Tao QS, Huang HL, Chai Y, et al (2012). Interleukin-6 upregulates the expression of interleukin-15 is associated with MAPKs and PI3-K signaling pathways in the human keratinocyte cell line, HaCaT. Mol Biol Rep, 39, 4201-5. https://doi.org/10.1007/s11033-011-1205-4
  26. Tjiong MY, van der Vange N, ten Kate FJ, et al (1999). Increased IL-6 and IL-8 levels in cervicovaginal secretions of patients with cervical cancer. Gynecol Oncol, 73, 285-91. https://doi.org/10.1006/gyno.1999.5358
  27. Upadhyay R, Jain M, Kumar S, Ghoshal UC, Mittal B (2008). Association of interleukin-6 (-174G>C) promoter polymorphism with risk of squamous cell esophageal cancer and tumor location: an exploratory study. Clin Immunol, 128, 199-204. https://doi.org/10.1016/j.clim.2008.03.519
  28. Vairaktaris E, Yiannopoulos A, Vylliotis A, et al (2006). Strong association of interleukin-6 -174 G>C promoter polymorphism with increased risk of oral cancer. Int J Biol Markers, 21, 246-50.
  29. Wei LH, Kuo ML, Chen CA, et al (2001a). Interleukin-6 in cervical cancer: the relationship with vascular endothelial growth factor. Gynecol Oncol, 82, 49-56. https://doi.org/10.1006/gyno.2001.6235
  30. Wei LH, Kuo ML, Chen CA, et al (2001b). The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mcl-1 through a PI 3-K/Akt pathway. Oncogene, 20, 5799-809. https://doi.org/10.1038/sj.onc.1204733
  31. Xu B, Niu XB, Wang ZD, et al (2011). IL-6 -174G>C polymorphism and cancer risk: a meta-analysis involving 29, 377 cases and 37, 739 controls. Mol Biol Rep, 38, 2589-96. https://doi.org/10.1007/s11033-010-0399-1
  32. Yang S, Jia C, Zhu H, Han S (2012). CYP1A1 Ile462Val polymorphism and cervical cancer: evidence from a metaanalysis. Tumour Biol, 33, 2265-72. https://doi.org/10.1007/s13277-012-0488-y
  33. Zhang H, Xu Y, Li L, Liu R, Ma B (2012). The interleukin-6-174G/C polymorphism and prostate cancer risk: a systematic review and meta-analysis. Urol Int, 88, 447-53. https://doi.org/10.1159/000335207
  34. Zhang HL, Zhang YJ (2013). A systemic assessment of the association between tumor necrosis factor alpha 308 G/A polymorphism and risk of cervical cancer. Tumor Biol, 34, 1659-65. https://doi.org/10.1007/s13277-013-0699-x
  35. Zhang ZY, Jin XY, Wu R, et al (2012). Meta-analysis of the association between GSTM1 and GSTT1 gene polymorphisms and cervical cancer. Asian Pac J Cancer Prev, 13, 815-9. https://doi.org/10.7314/APJCP.2012.13.3.815
  36. Zhou X, Gu Y, Zhang SL (2012). Association between p53 codon 72 polymorphism and cervical cancer risk among Asians: a HuGE review and meta-analysis. Asian Pac J Cancer Prev, 13, 4909-14. https://doi.org/10.7314/APJCP.2012.13.10.4909
  37. Zhu J, Wu L, Kohlmeier M, Ye F, Cai W (2013). Association between MTHFR C677T, MTHFR A1298C and MS A2756G polymorphisms and risk of cervical intraepithelial neoplasia II/III and cervical cancer: a meta-analysis. Mol Med Rep, 8, 919-27.

Cited by

  1. Association between six genetic variants of IL-17A and IL-17F and cervical cancer risk: a case–control study vol.36, pp.5, 2015, https://doi.org/10.1007/s13277-015-3041-y
  2. Polymorphisms of the interleukin 6 gene and additional gene–gene interaction contribute to cervical cancer susceptibility in Eastern Chinese women vol.294, pp.6, 2016, https://doi.org/10.1007/s00404-016-4175-x
  3. Genetic variations in interleukin-6 polymorphism and the association with susceptibility and overall survival of osteosarcoma vol.37, pp.7, 2016, https://doi.org/10.1007/s13277-016-4876-6
  4. Association Between the IL-6 rs1800795 Polymorphism and the Risk of Cervical Cancer: A Meta-Analysis of 1210 Cases and 1525 Controls vol.16, pp.5, 2017, https://doi.org/10.1177/1533034616672806
  5. Functional Variants with Acute Myeloid Leukemia in Turkish Patients vol.20, pp.9, 2016, https://doi.org/10.1089/gtmb.2016.0036
  6. on cervical cancer risk among Uygur females from China: A case-control study pp.23249269, 2018, https://doi.org/10.1002/mgg3.516
  7. -174G>C (rs1800795) polymorphism with cervical cancer susceptibility vol.38, pp.5, 2018, https://doi.org/10.1042/BSR20181071